Clinical Trials Browser

Suspended × Cyclophosphamide × 1 year × Clear all

NCT04799275 2026-03-19

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Phase 2/3 Suspended

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04301076 2026-03-18

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Phase 1 Suspended

LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03150693 2026-03-02

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Phase 3 Suspended

Burkitt Lymphoma

NCT03467386 2026-02-17

Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia

Phase 1 Suspended

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06968195 2026-02-10

Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma

Phase 1 Suspended

Gastrointestinal

Carcinoma, Hepatocellular

NCT04850495 2026-02-06

Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

Phase 1 Suspended

Lymphoma, Large B-Cell, Diffuse

NCT04855253 2026-01-15

Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

Phase 1/2 Suspended

Lymphoma, Large B-Cell, Diffuse

NCT05989828 2026-01-14

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Phase 1 Suspended

Triple Negative Breast Neoplasms

NCT06692452 2026-01-07

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Phase 2 Suspended

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

NCT05400122 2025-11-12

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Phase 1 Suspended

GastrointestinalLymphoidMyeloidOther hematologic neoplasmPlasma cell

Esophageal Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasm Metastasis, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04539366 2025-11-03

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

Phase 1 Suspended

Neuroblastoma, Osteosarcoma

NCT02354547 2025-05-30

A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors

Phase 1 Suspended

Neoplasms

NCT04668365 2025-04-25

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Phase 2 Suspended

Congenital Abnormalities, Lymphoma, Large B-Cell, Diffuse